"RNA, Small Interfering" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
Descriptor ID |
D034741
|
MeSH Number(s) |
D13.150.650.700 D13.444.735.150.700 D13.444.735.790.552.875
|
Concept/Terms |
RNA, Small Interfering- RNA, Small Interfering
- Interfering RNA, Small
- Short Interfering RNA
- Interfering RNA, Short
- RNA, Short Interfering
- Small Interfering RNA
- siRNA
Piwi-Interacting RNA- Piwi-Interacting RNA
- Piwi Interacting RNA
- RNA, Piwi-Interacting
- RNA, Piwi Interacting
- piRNA
Short Hairpin RNA- Short Hairpin RNA
- Hairpin RNA, Short
- RNA, Short Hairpin
- Small Hairpin RNA
- Hairpin RNA, Small
- RNA, Small Hairpin
- shRNA
Repeat-Associated siRNA- Repeat-Associated siRNA
- Repeat Associated siRNA
- siRNA, Repeat-Associated
- siRNA, Repeat Associated
Scan RNA- Scan RNA
- scnRNA
- Small Scan RNA
- RNA, Small Scan
- Scan RNA, Small
- RNA, Scan
Trans-Acting siRNA- Trans-Acting siRNA
- Trans Acting siRNA
- tasiRNA
- siRNA, Trans-Acting
- siRNA, Trans Acting
|
Below are MeSH descriptors whose meaning is more general than "RNA, Small Interfering".
Below are MeSH descriptors whose meaning is more specific than "RNA, Small Interfering".
This graph shows the total number of publications written about "RNA, Small Interfering" by people in this website by year, and whether "RNA, Small Interfering" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 1 | 0 | 1 |
2006 | 1 | 0 | 1 |
2007 | 1 | 2 | 3 |
2008 | 2 | 1 | 3 |
2009 | 2 | 1 | 3 |
2010 | 2 | 0 | 2 |
2011 | 2 | 0 | 2 |
2012 | 1 | 1 | 2 |
2013 | 5 | 0 | 5 |
2015 | 2 | 1 | 3 |
2017 | 1 | 1 | 2 |
2018 | 0 | 1 | 1 |
2020 | 3 | 0 | 3 |
2021 | 1 | 1 | 2 |
2022 | 0 | 3 | 3 |
2023 | 0 | 4 | 4 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "RNA, Small Interfering" by people in Profiles.
-
Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024 Aug; 26(8):3223-3237.
-
Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention. Atherosclerosis. 2024 Apr; 391:117472.
-
Safety and Tolerability of Inclisiran for?Treatment of Hypercholesterolemia in?7 Clinical Trials. J Am Coll Cardiol. 2023 12 12; 82(24):2251-2261.
-
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation. 2024 01 30; 149(5):354-362.
-
Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. Atherosclerosis. 2023 12; 386:117354.
-
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023 01 07; 44(2):129-138.
-
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc Drugs Ther. 2024 Jun; 38(3):493-503.
-
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022 12 21; 43(48):5047-5057.
-
Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. S Afr Med J. 2022 05 31; 112(6):426-432.
-
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. Curr Opin Lipidol. 2021 08 01; 32(4):213-218.